CClinicalTrials.gg
CompletedNCT07693985MBC_MMEUpdated Jul 9, 2026

Multimodal Exercise and Education Program in Metastatic Breast CancerMostrar más líneas

An interventional study of Multimodal Oncology-Based Intervention for Metastatic Breast Cancer in Metastatic Breast Cancer, Cancer-Related Fatigue and Quality of Life, sponsored by University of Valencia. Completed at 1 site in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by University of Valencia · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Jan 2024, registered Jun 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

This longitudinal pre-post study evaluates the effects of a 12-week community-based multimodal intervention combining supervised physical exercise and health education in women with metastatic breast cancer receiving active systemic treatment. The intervention includes Nordic walking, Tai Chi, and structured health education workshops. The main outcomes are changes in health-related quality of life and cancer-related fatigue, assessed before and after the intervention using validated EORTC questionnaires.Mostrar más líneas

Read the detailed description

Women with metastatic breast cancer receiving active systemic treatment frequently experience impaired health-related quality of life, cancer-related fatigue, and limitations in daily functioning. Supportive care strategies that combine physical exercise, education, and symptom self-management may help improve these outcomes, although evidence in women living with metastatic breast cancer remains limited.

This study is a longitudinal pre-post intervention study conducted in women with metastatic breast cancer receiving active systemic treatment. Eligible participants are women with metastatic breast cancer, preserved functional status, and the ability to ambulate independently. Participants are assessed at baseline and after completion of the intervention.

The intervention lasts 12 weeks and consists of a community-based multimodal program combining supervised physical exercise and health education. The exercise component includes two 60-minute supervised sessions per week: one session of Nordic walking and one session of Tai Chi. Nordic walking sessions are supervised by a physiotherapist, and Tai Chi sessions are led by a trained instructor. Exercise sessions are adapted to participants' physical capacity and clinical condition.

In addition to the exercise component, participants attend structured health education workshops throughout the program. These sessions address topics relevant to women with metastatic breast cancer, including general aspects of metastatic breast cancer, systemic treatments and toxicity management, the benefits of physical exercise, nutrition and supplementation, sleep hygiene, emotional regulation, communication with the social environment, and aesthetic care during cancer treatment.

Health-related quality of life is assessed using the EORTC QLQ-C30 and the breast cancer-specific EORTC QLQ-BR45 questionnaires. Cancer-related fatigue is assessed using the EORTC QLQ-FA12 questionnaire. The study evaluates changes in global health status, functional domains, fatigue dimensions, and selected breast cancer-specific symptom and functional domains before and after the intervention.

The aim of the study is to determine whether a supervised, community-based multimodal program combining physical exercise and health education is associated with improvements in quality of life, functioning, and fatigue-related outcomes in women with metastatic breast cancer receiving active systemic treatment.

02

Conditions studied

  • Metastatic Breast Cancer
  • Cancer-Related Fatigue
  • Quality of Life

Keywords

  • Metastatic breast cancer
  • Quality of life
  • Supportive care
  • Physical exercise
  • Health education
03

In context

Breast Neoplasms

12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.

This study's enrollment of 37 is below the median of 72 across 9,303 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

University of Valencia is the lead sponsor of 349 studies on the registry; 73 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Women diagnosed with metastatic breast cancer.
  • Receiving active systemic treatment.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • Able to ambulate independently.
  • Able and willing to participate in the multimodal intervention program.
  • Provided written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Moderate or severe cognitive impairment.
  • Severe psychiatric illness.
  • Sensory impairment preventing participation in the intervention or assessments.
  • Chronic disabling conditions limiting participation in the planned activities.
  • Unstable bone metastases, according to medical judgment, associated with risk of fragility fracture.
  • Cardiac or respiratory disease limiting the capacity to perform physical activity.
  • Any other medical condition that, in the opinion of the treating oncologist, contraindicated participation in the program.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Multimodal Exercise and Health Education Program

    Participants receive a 12-week community-based multimodal intervention combining supervised physical exercise and health education. The exercise component includes one weekly Nordic walking session and one weekly Tai Chi session, each lasting 60 minutes. In addition, participants attend structured health education workshops addressing topics related to metastatic breast cancer, systemic treatment and toxicity management, physical exercise, nutrition, sleep hygiene, emotional regulation, communication, and aesthetic care during cancer treatment.

    Other: Multimodal Oncology-Based Intervention for Metastatic Breast Cancer

Interventions

  • OtherMultimodal Oncology-Based Intervention for Metastatic Breast Cancer

    Participants receive a 12-week community-based multimodal oncology intervention combining supervised physical exercise and health education. The exercise component consists of one weekly Nordic walking session and one weekly Tai Chi session, each lasting 60 minutes. In addition, participants attend structured health education workshops covering metastatic breast cancer, systemic treatment and toxicity management, safe physical exercise, nutrition, sleep hygiene, emotional regulation, communication, and aesthetic care during cancer treatment. The intervention aims to promote physical and emotional well-being, support self-management, and improve quality of life.

06

What researchers measure

Primary outcomes

  1. Change in Global Health Status/Quality of LifeMostrar más líneas

    Change in global health status/quality of life assessed using the EORTC QLQ-C30 global health status scale. Scores are transformed to a 0-100 scale, with higher scores indicating better global health status and quality of life.Mostrar más líneas

    Time frame: Baseline and after completion of the 12-week interventionMostrar más líneas

Secondary outcomes

  1. Change in Physical FunctioningMostrar más líneas

    Change in physical functioning assessed using the EORTC QLQ-C30 physical functioning scale. Scores are transformed to a 0-100 scale, with higher scores indicating better physical functioning.Mostrar más líneas

    Time frame: Baseline and after completion of the 12-week interventionMostrar más líneas

  2. Change in Role FunctioningMostrar más líneas

    Change in role functioning assessed using the EORTC QLQ-C30 role functioning scale. Scores are transformed to a 0-100 scale, with higher scores indicating better role functioning.Mostrar más líneas

    Time frame: Baseline and after completion of the 12-week interventionMostrar más líneas

  3. Change in Emotional FunctioningMostrar más líneas

    Change in emotional functioning assessed using the EORTC QLQ-C30 emotional functioning scale. Scores are transformed to a 0-100 scale, with higher scores indicating better emotional functioning.

    Time frame: Baseline and after completion of the 12-week interventionMostrar más líneas

  4. Change in Cancer-Related FatigueMostrar más líneas

    Change in fatigue assessed using the fatigue symptom scale of the EORTC QLQ-C30. Scores are transformed to a 0-100 scale, with higher scores indicating greater fatigue symptom burden.Mostrar más líneas

    Time frame: Baseline and after completion of the 12-week interventionMostrar más líneas

  5. Change in Multidimensional FatigueMostrar más líneas

    Change in multidimensional cancer-related fatigue assessed using the EORTC QLQ-FA12 questionnaire, including physical fatigue, emotional fatigue, cognitive fatigue, interference with daily life, and social dimension. Scores are transformed to a 0-100 scale, with higher scores indicating greater fatigue or impairment.Mostrar más líneas

    Time frame: Baseline and after completion of the 12-week intervention

  6. Change in Breast Cancer-Specific Quality of LifeMostrar más líneas

    Change in breast cancer-specific quality of life assessed using selected domains of the EORTC QLQ-BR45 questionnaire, including body image, future perspective, systemic therapy side effects, arm symptoms, breast symptoms, endocrine therapy symptoms, and skin and mucosal symptoms. Scores are transformed to a 0-100 scale. Higher scores indicate better functioning in functional scales and greater symptom burden in symptom scales.Mostrar más líneas

    Time frame: Baseline and after completion of the 12-week interventionMostrar más líneas

07

Study locations

1 site
  • Carmen García Gomariz
    Valencia, 46010, Spain
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data supporting the findings of this study may be made available to qualified researchers upon reasonable request to the corresponding author. Shared data may include baseline sociodemographic and clinical variables, intervention attendance, and EORTC QLQ-C30, QLQ-BR45, and QLQ-FA12 scores at baseline and post-intervention. Data sharing will be subject to ethical and data protection requirements and will require approval of a research proposal and a data access agreement.Mostrar más líneas

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07693985
Lead sponsor
University of Valencia
Responsible party
CARMEN GARCÍA GOMARIZ (Clinical professor, University of Valencia) — Principal investigator
First posted
Jul 9, 2026
Start date
Jan 12, 2024
Primary completion
Dec 17, 2025
Completion
Dec 17, 2025
Last update
Jul 9, 2026

Study contacts

Sergio Pascual-Solaz
principal investigator · a. Departament of Medical Oncology, Consorcio Hospital Provincial, Castellón 12005 Valencia, Spain

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion